The text outlines the financial information of Boston Scientific Corporation and its subsidiaries, including statements of operations, comprehensive income, balance sheets, stockholders' equity, and cash flows for the three and nine months ended September 30 in 2023 and 2022. It covers details on net sales, operating expenses, income taxes, assets, liabilities, and stockholder information. Additionally, it discusses the classification, valuation, and fair value measurements of derivative and nonderivative assets and liabilities, including three-level valuation hierarchy, recurring and non-recurring fair value measurements, as well as debt obligations, revolving credit facility, financial covenants, and debt instrument comparisons. The text provides a comprehensive overview of the company's financial standing and obligations, including analyses of various financial elements such as property, plant, and equipment, goodwill, intangible assets, debt, and equity.
The text provided is a comprehensive overview of Boston Scientific Corporation's financial performance and operations, including their net sales, net income, operational highlights, and strategic initiatives. It discusses the various segments of their business, such as Endoscopy, Urology, Neuromodulation, Cardiology, Peripheral Interventions, and growth in emerging markets. Additionally, it touches on financial summaries, management discussions, balance sheet analyses, and factors affecting financial performance and profitability. The company's emphasis on non-GAAP financial measures, compliance, critical accounting policies, liquidity, and forward-looking statements is also highlighted to provide investors with a detailed understanding of the company's financial standing and future outlook.
The company develops, manufactures, and sells medical devices globally, which exposes them to market risks such as currency exchange rates and interest rates. They manage these risks through a documented corporate risk management program, using derivative financial instruments. The company does not engage in speculative derivative transactions and ensures gains and losses on these instruments offset losses and gains on underlying hedged exposures. They manage currency risk through a combination of nonderivative and derivative instruments, with outstanding currency derivative instruments valued at $6.005 billion as of September 30, 2023. Regarding interest rate risk, they use interest rate derivative instruments, although none were outstanding as of September 30, 2023. The company's debt obligations primarily consist of fixed interest rates, with approximately 100 percent of total debt at fixed rates as of September 30, 2023. Further details on the company's derivative financial instruments can be found in their unaudited consolidated financial statements.
The company's management, led by the CEO and CFO, assessed the effectiveness of its disclosure controls and procedures as of September 30, 2023, finding them to be effective. They operate to ensure timely and accurate reporting of material information required by the SEC. Additionally, the company initiated a new global ERP system in 2022, with the implementation anticipated to extend over multiple years. The initial phases of this transition have already impacted the internal control over financial reporting, with further changes expected as subsequent implementation stages occur. These changes may require adjustments to ensure the continued effectiveness of the internal controls over financial reporting.
The text provides information on legal proceedings and directs the reader to refer to Note H for details on commitments and contingencies in the unaudited consolidated financial statements in the Quarterly Report on Form 10-Q.
Consider the risks outlined in Part I, Item 1A. Risk Factors of the most recent Annual Report on Form 10-K, as they could significantly impact the company's business, financial status, and future outcomes.
I understand that you will be sending the text in parts and I should wait until all parts are received before providing a summary. Please go ahead and send the text.
Sure, please go ahead and provide the text parts for me to summarize.
I'm ready to help summarize the text whenever you're ready to send it!
No director or officer adopted or terminated any trading arrangements during the quarter ended September 30, 2023.
The text contains various exhibits and certifications related to the financial reporting of Boston Scientific Corporation, including certificates of elimination, subsidiary issuers of guaranteed securities, and certifications of the Chief Executive Officer and Chief Financial Officer in compliance with the Sarbanes-Oxley Act of 2002. It also includes Inline XBRL documents, a cover page interactive data file, and the signature of the report duly authorized on November 1, 2023, by Daniel J. Brennan, the Executive Vice President and Chief Financial Officer of the company.
